Objectives Medicaid populations have been disproportionately affected by the opioid epidemic. In Georgia, opioid deaths have increased at more than twice the rate of the nation at large. It is unknown if certain populations within the Medicaid unduly receive opioid prescriptions or experience inappropriate prescribing of opioids. Thus, this study examines gender and insurance disparities in the use of opioids and the prevalence of indicators for potential inappropriate prescribing of opioids in the Georgia Medicaid population. Methods Using individual Georgia Medicaid pharmacy claims data from 2012, disparities across gender (male/female) and type of insurance (fee-for-service (FFS)/managed care (MC)) were examined for the general use of opioids and potential inappropriate prescribing practices by providers. These outcome measures were taken from previous clinical guidelines and expert panels. T-tests were conducted to estimate significance in disparities across gender and type of insurance. Key findings Average number of opioid prescriptions received and average days of supply of opioids were higher among men than women (P < 0.001), and among FFS patients than MC patients (P < 0.001). Similarly, average incidences of potential inappropriate prescribing of opioids were higher among men (1.41) than women (0.83) (P < 0.001), and among FFS patients (1.60) than MC patients (0.46) (P < 0.001).
Introduction
Prescription opioid misuse, inappropriate prescribing of opioids and deaths from opioid overdose are a growing public health concern in the United States. The number of written prescriptions for opioid medications rose from 75.5 to 209.5 million over the past decade and deaths related to opioids tripled from 1999 to 2012. [1] From 2000 to 2014, there was a 200% increase in opioid-related overdose deaths. [2] Opioid misuse, abuse and dependence account for increased healthcare utilization and associated healthcare costs. The total economic burden of prescription opioid overdose, abuse and dependence in the United States was estimated at $78.5 billion in 2013. [3] According to the Centers for Medicare and Medicaid Services, the opioid epidemic is disproportionately impacting Medicaid enrolees. [4] Data suggest that Medicaid enrolees are more likely to be prescribed opioids and are at higher risk for prescription drug overdose compared to non-Medicaid populations. [5] A study of Medicaid enrolees in 12 states found that 40% of Medicaid enrolees receiving opioid prescriptions for pain had at least one indicator of potentially inappropriate use or prescribing, defined as overlapping prescriptions of opioids, overlapping prescriptions of benzodiazepines and opioids, high daily dose of opioids (100 morphine milligram equivalents (MMEs) or greater), opioid rapid dose escalation, long-acting/extended release (LA/ER) opioid for acute pain conditions, overlapping LA/ER prescriptions and LA/ER prescriptions written for opioid 'na€ ıve' patients. [6] Moreover, Medicaid populations have high rates of substance use disorders (SUD), a risk factor for opioid abuse and overdose. [7] Research suggests that the financial cost of prescription opioid-related issues may be particularly burdensome for public healthcare payers such as state Medicaid programs. [8, 9] In Georgia, opioid-related overdose deaths are increasing at more than twice the rate of the nation at large. The prescription opioid overdose death rate per 100 000 persons in Georgia increased from 0.6 in 1999 to 6.8 in 2015, an increase of 1033%, while it increased from 1.4 to 7.0 per 100 000 persons in the USA, an increase of 400%, during the same time period. [10] To date, researchers have examined the prevalence of potentially inappropriate use and prescription of opioid analgesics in Emergency Departments, [11] among enrolees in the Truven Health MarketScan â Commercial Claims and Encounters database, [12] and among Medicaid enrolees in the MarketScan â Multi-State Medicaid database. [6] Although one prior study focuses on Medicaid enrolees, it does not provide information on specific state Medicaid populations. This study focuses on utilization of opioids among Georgia Medicaid enrolees, a vulnerable population at high risk for opioid misuse, abuse and overdose.
To develop targeted policies to address the opioid epidemic, first it is important to understand the disparities in the general use of opioids and the potential inappropriate prescribing of opioids in this population. While opioid overdose death rates among men and women differ in general (higher among men), little information exists on gender disparities in the Medicaid population on their use of opioids, and inappropriate prescribing of opioids. Moreover, no information exists on disparities across insurance types in the use of opioids, or inappropriate prescribing of opioids. Information on gender and insurance disparities on the use of opioids as well as on potential inappropriate prescribing practices could provide important insights to prescribers and policy makers seeking to improve medication utilization and health outcomes in these specific subpopulations.
Thus, the objective of this study was to examine gender (male/female) and insurance (fee-for-service (FFS)/managed care (MC)) disparities both in the use of opioids and in the prevalence of indicators for potential inappropriate prescribing practices of opioids by providers in the Georgia Medicaid population. The results of this study help inform practitioners and policy makers in monitoring the usage of opioids, improving prescribing practices, improving provider-patient communications and implementing policies that would result in reducing inappropriate prescribing practices.
Methods

Data
This study utilized individual pharmacy claims data from the Georgia Medicaid pharmacy claims database from January 2012 to December 2012. The study sample was restricted to individuals who were continuously enrolled, received an opioid prescription (short-or long-acting extended release opioids) during the study period and were between the ages of 18 and 64. Table 1 provides the list of all opioids used by Georgia Medicaid enrolees in the analyses. [13] Following previous literature, individuals with diagnoses of cancer were excluded from the study. [6, 12] Cancer diagnoses were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes including 338.3, 140-172.9, 174-215.9, 217-229.10 and 235-239.9. The final study sample included 638 829 observations representing 136 589 individuals. 
Measures
The outcome variables of interest in this study included indicators that identified (1) general opioid use by patients, and (2) potential inappropriate prescribing practices by providers. The outcome measures were adapted from previous clinical guidelines and expert panels. [14] [15] [16] [17] [18] At the individual level, indicators of general opioid use were presented by number of prescriptions received, types of prescriptions received, total days of supply of opioids and prescriptions received by type of diagnoses. Indicators of inappropriate prescribing practices by providers were presented using five indicators that include having (1) overlapping opioid prescriptions, defined as opioid prescriptions that overlap by 7 days or more; (2) overlapping opioid and benzodiazepine prescriptions, defined as opioid and benzodiazepine prescriptions that overlap by 7 days or more; (3) overlapping opioid and Suboxone â (buprenorphine and naloxone) prescriptions, defined as opioid and Suboxone â prescriptions that overlap by 1 day or more; (4) long-acting/ extended release (LA/ER) opioids prescribed for acute pain; and (5) high daily doses of opioid prescriptions, defined as receiving more than 100 morphine milligram equivalents (MME).
Statistical analysis
The distribution of usage of opioids, benzodiazepines, Suboxone â and their combinations by all Georgia Medicaid enrolees who were receiving an opioid prescription during the study period were calculated. Utilization of opioids by days of supply and type of diagnoses were also analysed. The prevalence of indicators for inappropriate prescribing practices by providers was presented as percentage of individual beneficiaries, and the analyses were stratified by gender (male/female) and type of insurance (FFS/MC). T-tests were conducted to estimate significance in disparities across gender (male/female) and type of insurance (FFS/MC). As gender and type of insurance may also be correlated with age, we further conducted a multivariate analysis of covariance (MANCOVA) to examine the overall effect of gender and type of insurance on key-dependent variables while controlling for the covariate age. All statistical analyses were conducted in Stata version 14.2 (StataCorp LP, College Station, TX, USA).
Results
The average age of the study population was 35 years with men and women averaging at 42 and 34 years respectively (Table 2) . FFS patients (43 years) were older on average than MC patients (30 years). Among the sample population, 75.42% were female and 57.63% were enrolled in MC plans. On average, men received almost one more opioid prescription than women (men mean = 3.97; women mean = 3.08; P < 0.001), while FFS enrolees received almost 1.5 more opioid prescriptions than MC enrolees (FFS mean = 4.11; MC mean = 2.64; P < 0.001). More than one-third of the sample had three or more opioid prescriptions (34.31%) while 42% of men versus 32.36% of women and 42% FFS enrolees versus 28.63% MC enrolees received three or more opioid prescriptions. Moreover, 1.29% of the sample received 20 or more prescriptions and 26 individuals received 50 or more opioid prescriptions in 2012 (data not shown).
Average days of supply of opioids were higher among men (63.53) compared with women (38.07) (P < 0.001), and among FFS patients (64.88) compared with MC patients (27.15) (P < 0.001). Approximately 73% of the sample individuals received <30 total days of supply of opioids; 59.75% of men versus 75.80% of women and 60.48% FFS patients versus 81.43% MC patients received <30 total days of supply of opioids. Almost 14% of the sample individuals received more than 90 days of supply of opioids. Moreover, 7.81% of men and 4.12% of women, and 8% of FFS patients and 2.57% MC patients received 200-364 total days of supply of opioids. In addition, 744 (2.69%) men and 1468 (1.35%) women, and 1737 (3%) FFS patients and 475 (0.6%) MC patients, totalling 1.62% of the sample, received more than 365 days of supply of opioids (data not shown). Among the study sample 22% received a benzodiazepine prescription while 0.3% of the sample received a Suboxone â prescription. A higher proportion of men (21.43%) than women (19.68%) and a higher proportion of FFS patients (25.55%) than MC patients (15.98%) received both an opioid and a benzodiazepine prescription, totalling 20% of the study population. Table 3 presents diagnoses associated with the opioid prescriptions received by the study sample. Among the study sample, 24% had a diagnosis of chronic pain only while 8.53% of the sample had an acute pain only diagnosis. A larger percentage of men than women had a diagnosis of either acute pain or chronic pain only. However, a larger percentage of MC patients than FFS patients had acute pain only diagnosis while a larger percentage of FFS patients than MC patients had a chronic pain only diagnosis. The study sample had very few individuals (0.12%) with a diagnosis of opioid use disorders (OUD) only. About 21% of the sample had diagnoses of both acute and chronic pain conditions, with a higher percentage of men (28.05%) than women (18.97%), and higher percentage of FFS patients (25.77%) than MC patients (17.16%) experiencing these diagnoses. About 46% of the sample had other diagnoses (diagnoses other than acute pain, chronic pain, OUD or any combinations of them).
As for indicators of potential inappropriate prescribing practices by providers, about 6% of the sample received opioid/opioid overlapping prescriptions, 11.37% of the sample received opioid/benzodiazepine overlapping prescriptions, 0.12% of the sample received opioid/Suboxone â overlapping prescriptions, 2.87% of the sample received high daily doses and 0.97% of the sample received LA/ER prescriptions for acute pain (Table 4) . Results also indicate that a higher percentage of men (9.53%) than women (5.2%) and a higher percentage of FFS patients (9.76%) than MC patients (3.37%) received opioid/opioid overlapping prescriptions. A higher percentage of men (14.67%) than women (10.54%) also received opioid/benzodiazepine overlapping prescriptions. FFS patients (16.91%) received opioid/benzodiazepine overlapping prescriptions at more than twice the rate of MC patients (7.3%). Similarly, men (1.96%) received LA/ER opioid prescriptions for acute pain at more than twice the rate of women (0.71%), while FFS patients (1.84%) received them at more than five times the rate of MC patients (0.32%). Moreover, high daily doses of opioid prescriptions were received by men (4.84%) at a rate that was more than twice the rate of women (2.37%), and by FFS patients (4.19%) at a rate that was more than twice the rate of MC patients (1.9%). Overall, about 16% of the sample individuals experienced 1 or more incidences of indicators of potential inappropriate prescribing practices by providers, with a higher proportion of men (22.18%) experiencing more incidences than women (14.45%). FFS patients (23.49%) experienced more than twice the rate of incidences than MC patients (10.52%) in the sample. In addition, 5.81% of the sample experienced five or more incidences while 3.07% of the sample experienced 10 or more incidences of potential inappropriate prescribing practices by providers. A higher proportion of men than women in the sample experienced both five or more incidences and 10 or more incidences. The proportion of FFS patients (4.08%) experiencing five or more incidences was more than twice the rate of MC patients (1.75%), while it was four times greater for 10 or more incidences (5.49% versus 1.29% respectively).
Average incidences of potential inappropriate prescribing practices by providers were higher among men (1.41) in comparison with women (0.83) (P < 0.001), and among FFS patients (1.6) in comparison with MC patients (0.46) (P < 0.001). The average for FFS patients was more than three times the average for MC patients.
As both gender and insurance type are likely to be correlated with age, we also carried out a multivariate analysis of covariance (MANCOVA) to examine the overall effect of gender and insurance type on key-dependent variables (total days supply of opioids, total number of incidences of inappropriate prescribing practices), while controlling for the covariate age. Multivariate test indicated age (F = 5498.87, P < 0.001) as a significant covariate affecting the dependent variables. The MANCOVA results indicated that after controlling for the effects of the covariate age, there was a significant multivariate main effect of gender (F = 103.74, P < 0.001) and insurance type (F = 66.86, P < 0.001) on the dependent variables. The interaction between gender and insurance type also had significant negative effect on the dependent variables (F = 21.16, P < 0.001), indicating that women with managed care insurance are less likely to experience inappropriate incidences and higher average days supply of opioids compared with their counterparts. 
Discussion
Given the high level of attention and scrutiny associated with the prescribing of opioids, the finding that most opioid prescriptions in Georgia fall under appropriate and accepted prescribing practices is reassuring. Yet, there were a substantial number of individuals with opioid prescriptions that had characteristics that substantially elevated their risk of adverse health outcomes. This was evidenced by the fact that about one in six individuals in the study experienced one or more incidences of potential inappropriate prescribing practices. In addition, nearly half (45.72%) of the opioid use in this population was for conditions other than acute (9%) or chronic pain (24%) with an additional 20.80% of patients receiving opioids for both acute and chronic pain diagnoses. The relatively lower use of opioids for acute pain is encouraging given current recommendations with respect to the use of opioids for this diagnosis. [19] The study findings also indicated that men and FFS patients were receiving higher number of opioid, benzodiazepine and LA/ER opioid prescriptions as well as experiencing higher average days of supply of opioids in comparison with women and MC patients respectively. In Georgia, patients can select either FFS or MC for their Medicaid coverage. While most patients choose MC, patients who do not make an election are automatically assigned to FFS which is demographically comprised of older and sicker patients. While older and poorer populations tend to be sicker in general, there may be other factors which explain higher utilization of opioids among FFS patients and men in this population. MC formulary policies and prescribing protocols can also be more restrictive than FFS, limiting opioid utilization in MC. Previous literature also indicates misuse and abuse of opioids to be more prevalent among men than women, which might also explain higher utilization of opioids among men in this population. [20] While poor health conditions and restrictive formulary policies might explain some of these variations in opioid utilization, there might be other reasons such as demographic variations, socioeconomic differences or selection (bias) into certain health insurance plans that may account for these outcomes.
Similarly, men and FFS patients experienced higher levels of opioid/opioid and opioid/benzodiazepine overlapping prescriptions, LA/ER prescriptions for acute pain and high daily doses of opioids in comparison with women and MC patients respectively. While the finding of higher prevalence of opioid/opioid overlap among men is consistent with previous research on Medicaid populations, the findings on opioid/benzodiazepine overlap contrast with prior research. [6] It is also possible that the origins of pain (disease processes) in men differ from women and require more extensive treatment. Men may also delay seeking care longer than women, causing more difficulty for prescribers (e.g. pain is more severe and therefore difficult to treat) once care is finally sought. In addition, like opioid utilization, the fact that older and sicker people are more likely to be in FFS than MC and the restrictive nature of MC formularies may also help explain the high incidence rate of inappropriate prescribing practices among FFS Medicaid patients in Georgia.
The indicators of inappropriate prescribing practices examined in this study have been linked to opioid-related adverse health outcomes such as increased healthcare utilization, increased emergency department visits and overdose deaths. [21] [22] [23] The first step in reducing negative health outcomes in patients who must use opioids is to thoroughly understand the problem. Efforts are underway nationwide to reduce morbidity and mortality associated with opioid use. However, efforts aimed at this goal must be sensitive to legitimate patient needs related to relief of pain. For example, opioid use associated with the treatment of workrelated injuries should be optimized to avoid untoward outcomes such as long-term disability and improve pain management. [24] These efforts may bolster workforce and labour productivity among Medicaid populations in states such as Georgia.
It should also be recognized that in some cases, there may be medical reasons why certain drug dosages and combinations of opioids are prescribed even when it is known that the dose or combination of medications could place patients at increased risk. However, even with this in mind, there are clearly opportunities to improve medication use in patients using opioids. Strategies to reduce potential inappropriate prescribing might begin, as this study does, by alerting prescribers and policy makers to the numbers and types of patients for which opioid medication use may not be optimal.
Results from this study also indicate an opportunity to improve physicians' prescribing practices. Current educational efforts such as the CDC's Opioid Prescribing Guidelines have been created to provide evidence-based guidance regarding appropriate opioid use in clinical practice. [25] Professional organizations also have made an effort to reduce the negative outcomes stemming from inappropriate opioid prescribing through educational means. For example, the American Medical Association created a Task Force to Reduce Opioid Abuse which has assembled educational resources to bolster appropriate prescribing for pain management, reduce prescription opioid-related harm and combat drug diversion. In addition, researchers are now developing interventions to improve opioid prescribing. Recently, Leece et al. created an intervention based on implementation science and behaviour change theory to increase adherence to the Canadian Opioid Guideline among family physicians. [26] McCracken et al. pilot tested training experiences aimed at improving appropriate opioid prescribing. [27] Future research should continue to develop and evaluate the impact of educational efforts on physician prescribing practices.
Limitations
While this study has several strengths such as examining disparities in inappropriate prescribing of opioids across gender and insurance types, and providing a detail analysis of opioid use among the Medicaid population in Georgia, it has several limitations. First, pharmacy claims data show only filled prescriptions, not actual consumption, which may vary from the prescriptions received. Thus the results should be interpreted with caution. In addition, this study focuses only on Georgia Medicaid population aged 18-64. Therefore, the results may not be generalizable to the entire Medicaid population. Further, this is a cross-sectional study from year 2012 and is descriptive in nature. While Medicaid claims data from 2012 was chosen for the study due to its availability, to our knowledge this is the first study to examine opioid usage in Georgia Medicaid population. Finally, using ICD-9-CM codes to identify diagnoses has its own limitations as type of pain may not be classified properly or reported accurately.
Conclusions and policy implications
The presence of potential inappropriate prescribing practices in this study population highlights the need for attention to developing and evaluation of policies aimed at improving the prescribing of these medications. Creating and implementing policies designed to kerb potential inappropriate prescribing practices of opioids may improve adverse health outcomes and reduce opioid use disorder within the Medicaid population. [4] Efforts aimed at reducing opioid use disorder may include patient and prescriber education, more effective use of prescription drug monitoring programs, increased access to naloxone, appropriate treatment referral for patients with OUDs and strategies to reduce the supply of illicit opioids. Strategies to reduce the supply of opioids could include, for example, prescribing and dispensing limitations by payers and the rescheduling of hydrocodone products to Schedule II (which was done in 2014) in an attempt to kerb use and limit supply. Better identification of patients at risk for opioid use disorder, education of stakeholders (e.g. policy makers, prescribers and patients) and improved access to the rescue medications such as naloxone will be critical to improving outcomes for patients who must use opioids.
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